ADCT · Adc Therapeutics SA
United States · RS rating 43 · As of 2026-10-14
| Price | 1.45 USD |
|---|---|
| 1-day change | -14.7% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 98 / 83 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 34 / 21 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +86.7% |
| Sales growth Q/Q | +40.4% |
| Distance from 52-week high | +70.3% |
| Market cap (USD) | $503.7M |